Pediatrix reaffirms 2026 adjusted EBITDA outlook of $280 million-$300 million
MD•Second-quarter trends remained stable
Second-quarter payor mix held stable versus recent historical trends and internal expectations, avoiding the unfavorable shifts flagged elsewhere in healthcare.
No material changes were seen in other net revenue-related trends compared with recent periods.
2026 adjusted EBITDA outlook reaffirmed
Pediatrix reaffirmed full-year 2026 Adjusted EBITDA guidance of $280 million to $300 million.
